What’s ahead in ophthalmology: Pipeline milestones for Q2 2026
Key regulatory filings, phase 3 readouts, and trial enrollments to watch through June 30.
Several notable regulatory and clinical milestones in ophthalmology are expected in the second quarter of 2026. A potential FDA decision on a thyroid eye disease (TED) therapy under Priority Review, phase 3 topline data for a subcutaneous TED candidate, an anticipated NDA filing for a sustained-release wet AMD implant, and the anticipated completion of a rolling biologics license application (BLA) for retinitis pigmentosa (RP) are all on the near-term horizon. This roundup includes programs with a publicly disclosed regulatory or clinical milestone expected through June 30, 2026, and is not exhaustive of all ophthalmology pipeline activity during this period.